Impaired glucose tolerance and insulin resistance in heart failure: Underrecognized and undertreated?

Journal of Cardiac Failure

Volumn 16, Issue 9, 2010, Pages 761-768

  Mamas, Mamas A ^a,b   Deaton, Christi ^a,b   Rutter, Martin K ^a,b,d   Yuille, Martin ^b   Williams, Simon G ^c   Ray, Simon G ^b,c   New, John ^b,e   Gibson, J Martin ^b,e   Neyses, Ludwig ^a,b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c WYTHENSHAWE HOSPITAL   (United Kingdom)

^d Manchester Diabetes Centre   (United Kingdom)

^e SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

heart failure; Impaired glucose tolerance; insulin resistance; mechanisms

Indexed keywords

FATTY ACID; GLUCOSE; INCRETIN; METFORMIN; RESISTIN; TRIMETAZIDINE;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY ACID METABOLISM; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLYCOLYSIS; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BLOOD GLUCOSE; FATTY ACIDS; GLUCOSE INTOLERANCE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN RESISTANCE; METABOLIC SYNDROME X; METFORMIN; MYOCARDIUM; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 77956190021     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2010.05.027     Document Type: Review

References (72)

1. E. Leyden Asthma and diabetes mellitus Zeutschr Klin Med 3 1881 358 364
2. W.B. Kannel, M. Hjortland, and W.P. Castelli Role of diabetes in congestive heart failure: The Framingham study Am J Cardiol 34 1974 29 34
3. I.S. Thrainsdottir, T. Aspelund, G. Thorgeirsson, V. Gudnason, T. Hardarson, and K. Malmberg The association between glucose abnormalities and heart failure in the population-based Reykjavik study Diabetes Care 28 2005 612 616
4. M.I. Harris, K.M. Flegal, C.C. Cowie, M.S. Eberhardt, D.E. Goldstein, and R.R. Little Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey1988-1994 Diabetes Care 21 1998 518 524
5. M.S. Nieminen, D. Brutsaert, K. Dickstein, H. Drexler, F. Follath, V.P. Harjola EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population Eur Heart J 27 2006 2725 2736
6. K.F. Adams Jr., G.C. Fonarow, C.L. Emerman, T.H. LeJemtel, M.R. Costanzo, W.T. Abraham ADHERE Scientific Advisory Committee and Investigators Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J 149 2005 209 216
7. M.R. MacDonald, M.C. Petrie, N.M. Hawkins, J.R. Petrie, M. Fisher, and R. McKelvie Diabetes, left ventricular systolic dysfunction, and chronic heart failure Eur Heart J 29 2008 1224 1240
8. M.R. MacDonald, M.C. Petrie, F. Varyani, J. Ostergren, E.L. Michelson, J.B. Young CHARM Investigators Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme Eur Heart J 29 2008 1377 1385
9. M. Domanski, H. Krause-Steinrauf, P. Deedwania, D. Follmann, J.K. Ghali, and E. Gilbert The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial J Am Coll Cardiol 42 2003 914 922
10. D.M. Shindler, J.B. Kostis, S. Yusuf, M.A. Quinones, B. Pitt, and D. Stewart Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry Am J Cardiol 77 1996 1017 1020
11. N. Suskin, R.S. McKelvie, R.J. Burns, R. Latini, D. Pericak, and J. Probstfield Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure Eur Heart J 21 2000 1368 1375
12. R.M. Witteles, W.H. Tang, A.H. Jamali, J.W. Chu, G.M. Reaven, and M.B. Fowler Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link J Am Coll Cardiol 44 2004 78 81
13. J.W. Swan, S.D. Anker, C. Walton, I.F. Godsland, A.L. Clark, and F. Leyva Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure J Am Coll Cardiol 30 1997 527 532
14. K.M. Goode, J. John, A.S. Rigby, E.S. Kilpatrick, S.L. Atkin, and T. Bragadeesh Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus Heart 95 2009 917 923
15. C. Berry, M. Brett, K. Stevenson, J.J. McMurray, and J. Norrie Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure Heart 94 2008 296 304
16. M. Dunkelgrun, F. Schreiner, D.B. Schockman, S.E. Hoeks, H.H. Feringa, and D. Goei Usefulness of preoperative oral glucose tolerance testing for perioperative risk stratification in patients scheduled for elective vascular surgery Am J Cardiol 101 2008 526 529
17. M. Lankisch, R. Futh, D. Schotes, B. Rose, H. Lapp, and W. Rathmann High prevalence of undiagnosed impaired glucose regulation and diabetes mellitus in patients scheduled for an elective coronary angiography Clin Res Cardiol 95 2006 80 87
18. M. Ishihara, I. Inoue, T. Kawagoe, Y. Shimatani, S. Kurisu, and T. Hata Is admission hyperglycemia in non-diabetic patients with acute myocardial infarction a surrogate for previously undiagnosed abnormal glucose tolerance? Eur Heart J 27 2006 2413 2419
19. A.A. Motala, and M.A. Omar The value of glycosylated haemoglobin as a substitute for the oral glucose tolerance test in the detection of impaired glucose tolerance (IGT) Diabetes Res Clin Pract 17 1992 199 207
20. A.M. Salmasi, and M. Dancy The glucose tolerance test, but not HbA(1c), remains the gold standard in identifying unrecognized diabetes mellitus and impaired glucose tolerance in hypertensive subjects Angiology 56 2005 571 579
21. E. Mannucci, A. Ognibene, I. Sposato, M. Brogi, G. Gallori, and G. Bardini Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance Acta Diabetol 40 2003 181 186
22. W. Doehner, M. Rauchhaus, P. Ponikowski, I.F. Godsland, S. von Haehling, and D.O. Okonko Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure J Am Coll Cardiol 46 2005 1019 1026
23. F. Tassone, L. Gianotti, F. Rolfo, G. Visconti, G. Borretta, and M. Feola B-type natriuretic peptide levels and insulin resistance in patients with severe ischemic myocardial dysfunction J Endocrinol Invest 2009 Mar 25 [Epub ahead of print]
24. H.C. Gerstein, K. Swedberg, J. Carlsson, J.J. McMurray, E.L. Michelson, B. Olofsson CHARM Program Investigators The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program Arch Intern Med 168 2008 1699 1704
25. M. Kosiborod, S.E. Inzucchi, J.A. Spertus, Y. Wang, F.A. Masoudi, and E.P. Havranek Elevated admission glucose and mortality in elderly patients hospitalized with heart failure Circulation 119 2009 1899 1907
26. E.C. Knudsen, I. Seljeflot, M. Abdelnoor, J. Eritsland, A. Mangschau, and H. Arnesen Abnormal glucose regulation in patients with acute ST-elevation myocardial infarction - a cohort study on 224 patients Cardiovasc Diabetol 8 2009 6
27. E. Ingelsson, J. Sundström, J. Arnlöv, B. Zethelius, and L. Lind Insulin resistance and risk of congestive heart failure JAMA 294 2005 334 341
28. I.S. Thrainsdottir, T. Aspelund, T. Hardarson, K. Malmberg, G. Sigurdsson, and G. Thorgeirsson Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavík Study Eur J Cardiovasc Prev Rehabil 12 2005 465 471
29. C. Held, H.C. Gerstein, S. Yusuf, F. Zhao, L. Hilbrich, C. Anderson ONTARGET/TRANSCEND Investigators Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk Circulation 115 2007 1371 1375
30. L. Amato, G. Paolisso, F. Cacciatore, N. Ferrara, P. Ferrara, and S. Canonico Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group Diabetes Metab 23 1997 213 218
31. S. Yusuf, J.B. Ostergren, H.C. Gerstein, M.A. Pfeffer, K. Swedberg, C.B. Granger Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure Circulation 112 2005 48 53
32. A. Tenenbaum, M. Motro, E.Z. Fisman, J. Leor, D. Freimark, and V. Boyko Functional class in patients with heart failure is associated with the development of diabetes Am J Med 114 2003 271 275
33. A.H. Berg, and P.E. Scherer Adipose tissue, inflammation, and cardiovascular disease Circ Res 96 2005 939 949
34. M.A. Mamas, and L. Neyses Cardiac metabolism; from bench to bedside diabetic cardiomyopathy, a disease of cardiac metabolism? D. Rowlands, B. Clarke, Recent Advances in Cardiology 2007 Royal Society of Medicine Press Ltd London, UK 27 39
35. H. Ashrafian, M.P. Frenneaux, and L.H. Opie Metabolic mechanisms in heart failure Circulation 116 2007 434 448
36. R.M. Witteles, and M.B. Fowler Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options J Am Coll Cardiol 51 2008 93 102
37. Y. Matsuzawa Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease Nat Clin Pract Cardiovasc Med 3 2006 35 42
38. H. Katagiri, T. Yamada, and Y. Oka Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals Circ Res 101 2007 27 39
39. P. Mathieu, I. Lemieux, and J.P. Després Obesity, inflammation, and cardiovascular risk Clin Pharmacol Ther 87 2010 407 416
40. C.M. Steppan, S.T. Bailey, S. Bhat, E.J. Brown, R.R. Banerjee, and C.M. Wright The hormone resistin links obesity to diabetes Nature 409 2001 307 312
41. H.S. Jung, K.H. Park, Y.M. Cho, S.S. Chung, H.J. Cho, and S.Y. Cho Resistin is secreted from macrophages in atheromas and promotes atherosclerosis Cardiovasc Res 69 2006 76 85
42. L. Bertrand, S. Horman, C. Beauloye, and J.L. Vanoverschelde Insulin signalling in the heart Cardiovasc Res 79 2008 238 248
43. Z. Luo, Y. Zhang, F. Li, J. He, H. Ding, L. Yan, and H. Cheng Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells Endocrine 36 2009 60 69
44. M.T. Gentile, C. Vecchione, G. Marino, A. Aretini, A. Di Pardo, and G. Antenucci Resistin impairs insulin-evoked vasodilation Diabetes 57 2008 577 583
45. D.S. Frankel, R.S. Vasan, D'Agostino R.B. Sr, E.J. Benjamin, D. Levy, and T.J. Wang Resistin, adiponectin, and risk of heart failure the Framingham offspring study J Am Coll Cardiol 53 2009 754 762
46. J. Butler, A. Kalogeropoulos, V. Georgiopoulou, N. de Rekeneire, N. Rodondi, A.L. Smith Health ABC Study Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study Arterioscler Thromb Vasc Biol 29 2009 1144 1149
47. Y. Takeishi, T. Niizeki, T. Arimoto, N. Nozaki, O. Hirono, and J. Nitobe Serum resistin is associated with high risk in patients with congestive heart failure - a novel link between metabolic signals and heart failure Circ J 71 2007 460 464
48. M. Kim, J.K. Oh, S. Sakata, I. Liang, W. Park, and R.J. Hajjar Role of resistin in cardiac contractility and hypertrophy J Mol Cell Cardiol 45 2008 270 280
49. D. An, and B. Rodrigues Role of changes in cardiac metabolism in development of diabetic cardiomyopathy Am J Physiol Heart Circ Physiol 291 2006 H1489 H1506
50. J.J. Luiken, S.L. Coort, D.P. Koonen, D.J. van der Horst, A. Bonen, and A. Zorzano Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters Pflugers Arch 448 2004 1 15
51. M.L. Grundleger, and S.W. Thenen Decreased insulin binding, glucose transport, and glucose metabolism in soleus muscle of rats fed a high fat diet Diabetes 31 1982 232 237
52. B.N. Finck, and D.P. Kelly Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart J Mol Cell Cardiol 34 2002 1249 1257
53. B.N. Finck The role of the peroxisome proliferator-activated receptor alpha pathway in pathological remodeling of the diabetic heart Curr Opin Clin Nutr Metab Care 7 2004 391 396
54. P. Pillutla, Y.C. Hwang, A. Augustus, M. Yokoyama, H. Yagyu, and T.P. Johnston Perfusion of hearts with triglyceride-rich particles reproduces the metabolic abnormalities in lipotoxic cardiomyopathy Am J Physiol Endocrinol Metab 288 2005 E1229 E1235
55. Y.T. Zhou, P. Grayburn, A. Karim, M. Shimabukuro, M. Higa, and D. Baetens Lipotoxic heart disease in obese rats: implications for human obesity Proc Natl Acad Sci U S A 97 2000 1784 1789
56. H. Tuunanen, E. Engblom, A. Naum, M. Scheinin, K. Nagren, and J. Airaksinen Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction J Card Fail. 12 2006 644 652
57. L.R. Peterson, P. Herrero, K.B. Schechtman, S.B. Racette, A.D. Waggoner, and Z. Kisrieva-Ware Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women Circulation 109 2004 2191 2196
58. Y. Yazaki, M. Isobe, W. Takahashi, H. Kitabayashi, O. Nishiyama, and M. Sekiguchi Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course Heart 81 1999 153 159
59. M.C. Towler, and D.G. Hardie AMP-activated protein kinase in metabolic control and insulin signaling Circ Res 100 2007 328 341
60. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 854 865
61. F.A. Masoudi, S.E. Inzucchi, Y. Wang, E.P. Havranek, J.M. Foody, and H.M. Krumholz Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study Circulation 111 2005 583 590
62. D.T. Eurich, S.R. Majumdar, F.A. McAlister, R.T. Tsuyuki, and J.A. Johnson Improved clinical outcomes associated with metformin in patients with diabetes and heart failure Diabetes Care 28 2005 2345 2351
63. EMC. Glucophage 500 mg and 850 mg film coated tablets. Available online at: http://emc.medicines.org.uk/document.aspx?documentId=1043#contraindications. Accessed July 3, 2009.
64. J.S. Shaw, R.L. Wilmot, and E.S. Kilpatrick Establishing pragmatic estimated GFR thresholds to guide metformin prescribing Diabet Med 24 2007 1160 1163
65. A.K. Wong, M.A. AlZadjali, A.M. Choy, and C.C. Lang Insulin resistance: a potential new target for therapy in patients with heart failure Cardiovasc Ther 26 2008 203 213
66. L. Kay, C. Finelli, and J. Aussedat Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: effects on the energy state and mitochondrial function Am J Cardiol 76 1995 45B 49B
67. P.F. Kantor, A. Lucien, R. Kozak, and G.D. Lopaschuk The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase Circ Res 86 2000 580 588
68. H. Tuunanen, E. Engblom, A. Naum, K. Ngren, M. Scheinin, and B. Hesse Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy Circulation 118 2008 1250 1258
69. G. Fragasso, A. Palloshi, P. Puccetti, C. Silipigni, A. Rossodivita, and M. Pala A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure J Am Coll Cardiol 48 2006 992 998
70. M.A. Nauck Unraveling the science of incretin biology Am J Med 122 2009 S3 10
71. L.A. Nikolaidis, D. Elahi, T. Hentosz, A. Doverspike, R. Huerbin, and L. Zourelias Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy Circulation 110 2004 955 961
72. G.G. Sokos, L.A. Nikolaidis, S. Mankad, D. Elahi, and R.P. Shannon Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 12 2006 694 699